High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial

@article{Papadimitriou2008HighdoseMA,
  title={High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial},
  author={Christos Papadimitriou and Urania Dafni and Achileas Anagnostopoulos and Georgios Vlachos and Zannis Voulgaris and Alexandros J Rodolakis and Gerassimos Aravantinos and Aris Bamias and George Bozas and E Kiosses and Georgios M Gourgoulis and Elias Efstathiou and M A Dimopoulos},
  journal={Bone Marrow Transplantation},
  year={2008},
  volume={41},
  pages={547-554}
}
The role of high-dose chemotherapy (HDCT) in epithelial ovarian cancer (EOC) remains controversial. This study was initiated to compare the efficacy and tolerability of HDCT as a consolidation approach in women with chemosensitive advanced EOC (FIGO stages IIC–IV). Patients who had achieved their first clinical complete remission after six cycles of conventional paclitaxel and carboplatin combination chemotherapy were randomly assigned to receive or not high-dose melphalan. The primary… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

A phase III randomised trial of sequential high dose chemotherapy (HDC) with peripheral blood stem cell support or standard dose chemotherapy (SDC) for first-line treatment of ovarian cancer

  • JA Ledermann, N Frickhofen, H Wandt, C Bengala, K Champion, A Hinke
  • J Clin Oncol
  • 2005

Mancuso S : stem cells in gynecology and obstetrics

  • C Aghajanian, D Fennelly, F Shapiro, R Waltzman, C O’Flaherty
  • Panmi - nerva Medica
  • 2004

Similar Papers

Loading similar papers…